Title |
Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study
|
---|---|
Published in |
Critical Care, May 2011
|
DOI | 10.1186/cc10228 |
Pubmed ID | |
Authors |
Kazuma Yamakawa, Satoshi Fujimi, Tomoyoshi Mohri, Hiroki Matsuda, Yasushi Nakamori, Tomoya Hirose, Osamu Tasaki, Hiroshi Ogura, Yasuyuki Kuwagata, Toshimitsu Hamasaki, Takeshi Shimazu |
Abstract |
Cross-talk between the coagulation system and inflammatory reactions during sepsis causes organ damage followed by multiple organ dysfunction syndrome or even death. Therefore, anticoagulant therapies have been expected to be beneficial in the treatment of severe sepsis. Recombinant human soluble thrombomodulin (rhTM) binds to thrombin to inactivate coagulation, and the thrombin-rhTM complex activates protein C to produce activated protein C. The purpose of this study was to examine the efficacy of rhTM for treating patients with sepsis-induced disseminated intravascular coagulation (DIC). |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 3 | 5% |
Japan | 2 | 3% |
United States | 1 | 2% |
Unknown | 57 | 90% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 18 | 29% |
Researcher | 9 | 14% |
Student > Ph. D. Student | 7 | 11% |
Student > Doctoral Student | 4 | 6% |
Student > Master | 4 | 6% |
Other | 11 | 17% |
Unknown | 10 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 43 | 68% |
Agricultural and Biological Sciences | 5 | 8% |
Nursing and Health Professions | 2 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
Business, Management and Accounting | 1 | 2% |
Other | 0 | 0% |
Unknown | 11 | 17% |